Copy to clipboard 
DePuy Synthes reports 2Q19 orthopedic revenue of USD $2,230.9MM, -1.3% vs. 2Q18.
- Knee sales declined in the U.S. due to competitors taking advantage of gaps in the DePuy Synthes portfolio. The decline was partially offset by mid-single-digit growth ex-U.S. Leadership believes the launch of Orthotaxy combined with a cementless knee product will drive the company to at or above market growth.
- Hip sales saw continued demand for the ACTIS, which is now the company’s number one selling stem in the U.S., and adoption of the KINCISE Surgical Impactor for hip procedures in the U.S.
- Spine sales experienced further declines, primarily in the U.S. The company is seeking to reverse this trend through innovation, calling out the second half launch of their Symfony product for complex cervical pathologies.
- Trauma growth was supported by market growth and newer products like the Femoral Recon Nails.
- U.S. price pressure for the quarter was 4% in spine and 2% for hips, knees and trauma.
- On the acquisition of Auris Health, company leadership highlighted the benefit of gaining access to robotics industry expertise via Dr. Fred Moll. Dr. Moll and his team are evaluating all DePuy Synthes digital surgery platforms, though the Orthotaxy launch remains “on track.”
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM).
| 2Q19 | 2Q18 | $ Chg | % Chg | |
| Joint Replacement | $862.2 | $867.5 | -$5.4 | -0.6% |
| Knees | $378.8 | $389.4 | -$10.6 | -2.7% |
| Hips | $370.8 | $367.4 | $3.4 | 0.9% |
| Extremities | $112.6 | $110.7 | $1.9 | 1.7% |
| Spine | $347.7 | $359.0 | -$11.3 | -3.1% |
| Trauma | $642.5 | $644.1 | -$1.6 | -0.2% |
| Sports Medicine | $174.2 | $172.4 | $1.8 | 1.1% |
| Orthobiologics | $99.6 | $103.9 | -$4.3 | -4.1% |
| Other (CMF) | $104.7 | $114.1 | -$9.3 | -8.2% |
| Total | $2,230.9 | $2,260.9 | -$30.0 | -1.3% |
| 1H19 | 1H18 | $ Chg | % Chg | |
| Joint Replacement | $1,708.5 | $1,735.4 | -$26.9 | -1.6% |
| Knees | $753.2 | $782.6 | -$29.4 | -3.8% |
| Hips | $741.3 | $736.6 | $4.7 | 0.6% |
| Extremities | $214.1 | $216.2 | -$2.1 | -1.0% |
| Spine | $702.1 | $719.5 | -$17.4 | -2.4% |
| Trauma | $1,296.9 | $1,308.0 | -$11.1 | -0.9% |
| Sports Medicine | $343.7 | $340.0 | $3.7 | 1.1% |
| Orthobiologics | $194.4 | $205.2 | -$10.8 | -5.3% |
| Other (CMF) | $188.4 | $203.0 | -$14.6 | -7.2% |
| Total | $4,433.9 | $4,511.0 | -$77.1 | -1.7% |
ORTHOWORLD estimates orthopaedic sales by geographic region as follows ($MM).
| Geographic Region | 2Q19 | 2Q18 | $ Chg | % Chg |
| US | $1,334.72 | $1,313.35 | $21.4 | 1.6% |
| Ex-US | $896.22 | $947.58 | -$51.4 | -5.4% |
| EMEA | $403.30 | $426.41 | -$23.1 | -5.4% |
| Asia Pacific | $318.16 | $331.65 | -$13.5 | -4.1% |
| Rest of World | $174.76 | $189.52 | -$14.8 | -7.8% |
| Total | $2,230.9 | $2,260.9 | -$30.0 | -1.3% |
Net earnings for all Johnson & Johnson revenue are as follows.
| 2Q19 | Amount ($MM) | % of Sales |
| Sales | $20,562.0 | |
| Cost of Sales | -$6,940.0 | 33.8% |
| Selling and Admin | -$5,546.0 | 27.0% |
| R & D | -$2,666.0 | 13.0% |
| Other | $197.0 | 1.0% |
| Net Earnings | $5,607.0 | 27.3% |
Sources: DePuy Synthes Companies of Johnson & Johnson; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
DePuy Synthes reports 2Q19 orthopedic revenue of USD $2,230.9MM, -1.3% vs. 2Q18.
Knee sales declined in the U.S. due to competitors taking advantage of gaps in the DePuy Synthes portfolio. The decline was partially offset by mid-single-digit growth ex-U.S. Leadership believes the launch of Orthotaxy combined with a...
DePuy Synthes reports 2Q19 orthopedic revenue of USD $2,230.9MM, -1.3% vs. 2Q18.
- Knee sales declined in the U.S. due to competitors taking advantage of gaps in the DePuy Synthes portfolio. The decline was partially offset by mid-single-digit growth ex-U.S. Leadership believes the launch of Orthotaxy combined with a cementless knee product will drive the company to at or above market growth.
- Hip sales saw continued demand for the ACTIS, which is now the company’s number one selling stem in the U.S., and adoption of the KINCISE Surgical Impactor for hip procedures in the U.S.
- Spine sales experienced further declines, primarily in the U.S. The company is seeking to reverse this trend through innovation, calling out the second half launch of their Symfony product for complex cervical pathologies.
- Trauma growth was supported by market growth and newer products like the Femoral Recon Nails.
- U.S. price pressure for the quarter was 4% in spine and 2% for hips, knees and trauma.
- On the acquisition of Auris Health, company leadership highlighted the benefit of gaining access to robotics industry expertise via Dr. Fred Moll. Dr. Moll and his team are evaluating all DePuy Synthes digital surgery platforms, though the Orthotaxy launch remains “on track.”
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM).
| 2Q19 | 2Q18 | $ Chg | % Chg | |
| Joint Replacement | $862.2 | $867.5 | -$5.4 | -0.6% |
| Knees | $378.8 | $389.4 | -$10.6 | -2.7% |
| Hips | $370.8 | $367.4 | $3.4 | 0.9% |
| Extremities | $112.6 | $110.7 | $1.9 | 1.7% |
| Spine | $347.7 | $359.0 | -$11.3 | -3.1% |
| Trauma | $642.5 | $644.1 | -$1.6 | -0.2% |
| Sports Medicine | $174.2 | $172.4 | $1.8 | 1.1% |
| Orthobiologics | $99.6 | $103.9 | -$4.3 | -4.1% |
| Other (CMF) | $104.7 | $114.1 | -$9.3 | -8.2% |
| Total | $2,230.9 | $2,260.9 | -$30.0 | -1.3% |
| 1H19 | 1H18 | $ Chg | % Chg | |
| Joint Replacement | $1,708.5 | $1,735.4 | -$26.9 | -1.6% |
| Knees | $753.2 | $782.6 | -$29.4 | -3.8% |
| Hips | $741.3 | $736.6 | $4.7 | 0.6% |
| Extremities | $214.1 | $216.2 | -$2.1 | -1.0% |
| Spine | $702.1 | $719.5 | -$17.4 | -2.4% |
| Trauma | $1,296.9 | $1,308.0 | -$11.1 | -0.9% |
| Sports Medicine | $343.7 | $340.0 | $3.7 | 1.1% |
| Orthobiologics | $194.4 | $205.2 | -$10.8 | -5.3% |
| Other (CMF) | $188.4 | $203.0 | -$14.6 | -7.2% |
| Total | $4,433.9 | $4,511.0 | -$77.1 | -1.7% |
ORTHOWORLD estimates orthopaedic sales by geographic region as follows ($MM).
| Geographic Region | 2Q19 | 2Q18 | $ Chg | % Chg |
| US | $1,334.72 | $1,313.35 | $21.4 | 1.6% |
| Ex-US | $896.22 | $947.58 | -$51.4 | -5.4% |
| EMEA | $403.30 | $426.41 | -$23.1 | -5.4% |
| Asia Pacific | $318.16 | $331.65 | -$13.5 | -4.1% |
| Rest of World | $174.76 | $189.52 | -$14.8 | -7.8% |
| Total | $2,230.9 | $2,260.9 | -$30.0 | -1.3% |
Net earnings for all Johnson & Johnson revenue are as follows.
| 2Q19 | Amount ($MM) | % of Sales |
| Sales | $20,562.0 | |
| Cost of Sales | -$6,940.0 | 33.8% |
| Selling and Admin | -$5,546.0 | 27.0% |
| R & D | -$2,666.0 | 13.0% |
| Other | $197.0 | 1.0% |
| Net Earnings | $5,607.0 | 27.3% |
Sources: DePuy Synthes Companies of Johnson & Johnson; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
